The market continues to shrink and adjust, raising concerns about a retreat in the Siasun Robot&Automation Sector. Can the deep-sea Technology Concept hold the flag and launch a counterattack?

Track the entire lifecycle of the main Sector.

cls.cnMar 23 21:22 ET

Guizhou Xinbang Pharmaceutical's subsidiary is embroiled in a bribery scandal; what is the impact?

① Company personnel stated that this matter currently has no impact on the company's operation, and the subsidiary mainly engages in in-hospital pharmaceutical wholesale. Even if penalized later, it will not involve qualification issues. ② Industry experts believe that the short-term impact is significant, while the long-term impact is minimal. In the short term, the principal company may be listed as untrustworthy due to the crime of unit bribery, which would exclude it from the bidding procurement of local hospitals in Guizhou for a period. However, in the long term, since it is not a quality issue, there are opportunities for repair.

cls.cnMar 4 09:08 ET

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

Tasly Pharmaceutical Group's net income has declined by 10%, and the progress of equity transfer may accelerate | Interpretations

① Tasly Pharmaceutical Group achieved a total operating revenue of 8.498 billion yuan in 2024, a decrease of 2.03% year-on-year; Net income attributable to the parent company was 0.956 billion yuan, a decrease of 10.78% year-on-year. ② The current Shareholders are actively advancing the transfer of shares and have begun to sort out and confirm the actual used Assets and subsidiary Assets of the company.

cls.cnFeb 24 10:10 ET

This week, 11 more companies have been added! Youngor Group and several other stocks have disclosed their plans for shareholding and repurchase loans, with a complete list of related A-shares.

① The Share Buyback and Shareholding refinancing plan in the A-share market is steadily advancing. According to incomplete statistics from Caixin, 11 A-share listed companies announced and disclosed relevant information on Share Buyback and Shareholding refinancing this week (see attached table); ② Youngor Group has the highest special loan amount, totaling 0.7 billion yuan.

cls.cnFeb 15 20:14 ET

The 2024 Net income is expected to turn from loss to profit. Yueyang Forest & Paper "intensively" acquires old assets to enhance performance | Interpretations

① Yueyang Forest & Paper expects to turn from a loss to a profit in net income for 2024, boosted by the performance of Juntao Technology, which was acquired in late December last year; ② Affected by weak overall market demand, the company's paper product sales volume is expected to decline year-on-year in 2024, and the sales prices of paper products have decreased compared to the same period last year.

cls.cnJan 23 08:22 ET